Peptide Library

In clinical trials

Digestive & weight

Pemvidutide

Evidence

Clinical trials

Class

Dual GLP-1 and glucagon receptor agonist

/

Pemvidutide

KEY TAKEAWAY

Pemvidutide is a peptide that activates both the GLP-1 and glucagon receptors. Altimmune is developing it for fatty liver disease and obesity. Pemvidutide is not FDA-approved and is being tested in clinical trials.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

Dual GLP-1 and glucagon receptor agonist

Being studied for

Studied for fatty liver disease (MASH) and obesity

Key fact

Pemvidutide is not FDA-approved and is being tested in clinical trials.

Route

Weekly subcutaneous injection in trials

Evidence strength

Clinical trials

What it is

What it is

Pemvidutide is a peptide that activates both the GLP-1 and glucagon receptors. Altimmune is developing it for fatty liver disease and obesity.

How it works

How it works

GLP-1 activity reduces appetite, while glucagon activity may increase energy use and lower fat stored in the liver.

Regulatory status

Regulatory status

Pemvidutide is not FDA-approved and is being tested in clinical trials.

What it is used for

What it is used for

Studied for fatty liver disease (MASH) and obesity.

Side effects and risks

Side effects and risks

Nausea, vomiting and diarrhea were the most common effects in trials.

Citations

Citations

Pemvidutide: see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo